Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

By H. R. Büller, B. L. Davidson, Hervé Decousus, Alexander Gallus, M. Gent, Franco Piovella, Martin H Prins, G. E. Raskob, M. Berg-SegersvandenA.E., R. Cariou and 2 more. New England Journal of Medicine, 2003

806 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/3ec5984b42f2974cc2f86ff09353855f55035d3f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jeroen J. Bax
2. P. Lancellotti
3. G. Agnelli

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “In patients with acute PE and no indication for thrombolytic therapy, fondaparinux was associated with recurrent VTE and major bleeding rates similar to those obtained with intravenous UFH.(281) No proven cases of HIT have been reported with fondaparinux.”
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, neutral): “For long-term anticoagulation, LMWH, edoxaban, or rivaroxaban for$6 months is preferred because of improved efficacy over VKAs.”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, result): “In patients with acute PE and no indication for thrombolytic therapy, fondaparinux was associated with recurrent VTE and major bleeding rates similar to those obtained with intravenous UFH.(281) No proven cases of HIT have been reported with fondaparinux.”
• Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008, background): “1%) similar to those obtained with intravenous unfractionated heparin.(296) As no proven HIT case has ever been observed with fondaparinux, platelet count monitoring is not needed with this compound.”
• Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. (2006, methodology): “0%.(3-5,15) In contrast to our simple algorithm, a recent study(13) used a more complex flowchart with sequential testing that included clinical probability assessment, D-dimer assay, CUS, CT, as well as pulmonary angiography to exclude pulmonary embolism in patients with high likelihood and negativ”
• Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study (2005, neutral): “Iliac or caval deep-vein thrombosis, n (%) 74 (37) 85 (42)”